Research programme: Zika virus vaccine - GT Biopharma
Latest Information Update: 28 Apr 2020
At a glance
- Originator University of Pittsburgh
- Developer GT Biopharma; University of Pittsburgh
- Class Antivirals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Zika virus infection
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for research development in Zika-virus-infection in USA
- 28 Apr 2020 No recent reports of development identified for research development in Zika-virus-infection(Prevention) in USA
- 07 Aug 2017 Oxis International is now called GT Biopharma
Development Overview
Introduction
Oxis Biotech, a subsidiary of GT Biopharma (formerly Oxis International), is developing small molecule chemical inhibitors for prevention and treatment of Zika virus infection. The inhibitors target non-structural proteins, thereby blocking Zika virus replication. Early research is underway in the US.
In August 2017, Oxis International changed its name to GT Biopharma [1] .
As at April 2020, no recent reports of development had been identified for research development in Zika-virus-infection in USA, research development in Zika-virus-infection (Prevention) in USA.
Drug Properties & Chemical Synopsis
- Formulation unspecified
- Class Antivirals, Small molecules
- Mechanism of Action Undefined mechanism
-
WHO ATC code
J07B-X (Other viral vaccines)
-
EPhMRA code
J7E (Viral Vaccines)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Zika virus infection | - | - | No development reported (Research) | USA | unspecified / unspecified | GT Biopharma, University of Pittsburgh | 28 Apr 2020 |
| Zika virus infection | - | Prevention | No development reported (Research) | USA | unspecified / unspecified | GT Biopharma, University of Pittsburgh | 28 Apr 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| University of Pittsburgh | Originator | USA |
| University of Pittsburgh | Owner | USA |
| GT Biopharma | Collaborator | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Apr 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Zika-virus-infection in USA Updated 28 Apr 2020 |
| 28 Apr 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Zika-virus-infection(Prevention) in USA Updated 28 Apr 2020 |
| 07 Aug 2017 | Company Involvement | Oxis International is now called GT Biopharma Updated 10 Aug 2017 |
| 28 Mar 2016 | Phase Change | Early research in Zika virus infection (Prevention) in USA (unspecified route) Updated 05 Apr 2016 |
| 28 Mar 2016 | Phase Change | Early research in Zika virus infection in USA (unspecified route) Updated 05 Apr 2016 |
References
-
GT BIOPHARMA, INC. (OXIS) ANNOUNCES CORPORATE UPDATE CONFERENCE CALL WITH INCOMING CEO DR. KATHLEEN CLARENCE-SMITH AND CHAIRMAN ANTHONY CATALDO.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG